LCTX
- Lineage Cell Therapeutics, Inc.
()
Overview
Company Summary
Lineage Cell Therapeutics, Inc. (formerly known as BioTime, Inc.) is a biotechnology company that specializes in the development and commercialization of novel cell-based therapies. The company focuses on utilizing its proprietary pluripotent stem cell technology platform to develop regenerative medicine solutions for a variety of degenerative diseases and conditions.
Lineage Cell Therapeutics is known for its unique approach, which involves utilizing carefully selected pluripotent stem cells to create specialized cell types. These cells can then be used to develop therapeutic products that target specific diseases or conditions. The company's technology has the potential to transform the treatment landscape for a wide range of medical conditions, including age-related macular degeneration (AMD), spinal cord injuries, cancer, and various neurological disorders.
One of Lineage's key areas of focus is in the field of ophthalmology. The company has developed OpRegen�, an investigational new drug for the treatment of the advanced form of dry AMD. This therapy aims to replace damaged or dysfunctional retinal cells with functional retinal pigment epithelium (RPE) cells derived from pluripotent stem cells. By restoring vision through the regeneration of these cells, Lineage Cell Therapeutics hopes to provide a significant benefit to patients suffering from this degenerative eye disease.
Additionally, Lineage Cell Therapeutics is actively working on developing cell-based therapies for the treatment of spinal cord injuries. The company's transplantation program involves the use of OPC1, specialized oligodendrocyte progenitor cells, to restore function and promote neural repair in patients with spinal cord damage.
Overall, Lineage Cell Therapeutics' focus on advancing regenerative therapies using its pluripotent stem cell technology platform demonstrates its commitment to developing innovative treatments for various debilitating diseases and conditions.